These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12853000)

  • 1. [PK/PD modeling of aminoglycoside nephrotoxicity].
    Rougier F; Corvaisier S; Ducher M; Claude D; Jelliffe RW; Maire P
    Pathol Biol (Paris); 2003 Jun; 51(4):234-6. PubMed ID: 12853000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside nephrotoxicity: modeling, simulation, and control.
    Rougier F; Claude D; Maurin M; Sedoglavic A; Ducher M; Corvaisier S; Jelliffe R; Maire P
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1010-6. PubMed ID: 12604535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoglycoside nephrotoxicity.
    Rougier F; Claude D; Maurin M; Maire P
    Curr Drug Targets Infect Disord; 2004 Jun; 4(2):153-62. PubMed ID: 15180462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics and nephrotoxicity of aminoglycoside antibiotics].
    Marino A; Pisanti N
    Clin Ter; 1989 Jun; 129(6):421-8. PubMed ID: 2526703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.
    Lopez-Novoa JM; Quiros Y; Vicente L; Morales AI; Lopez-Hernandez FJ
    Kidney Int; 2011 Jan; 79(1):33-45. PubMed ID: 20861826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.
    Croes S; Koop AH; van Gils SA; Neef C
    Eur J Pharm Sci; 2012 Jan; 45(1-2):90-100. PubMed ID: 22094306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycoside-induced nephrotoxicity.
    Wargo KA; Edwards JD
    J Pharm Pract; 2014 Dec; 27(6):573-7. PubMed ID: 25199523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic monitoring of amikacin and gentamicin in routine clinical practice].
    Kacířová I; Grundmann M
    Vnitr Lek; 2015 Jan; 61(1):33-41. PubMed ID: 25693614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of aminoglycoside serum assays on clinical decisions and renal toxicity.
    Arroyo JC; Milligan WL; Davis J; Mitchell D
    South Med J; 1986 Mar; 79(3):272-6. PubMed ID: 3513326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
    Rougier F; Ducher M; Maurin M; Corvaisier S; Claude D; Jelliffe R; Maire P
    Clin Pharmacokinet; 2003; 42(5):493-500. PubMed ID: 12739987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The amikacin research program: a stepwise approach to validate dosing regimens in neonates.
    Smits A; Kulo A; van den Anker J; Allegaert K
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):157-166. PubMed ID: 27623706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glomerular nephrotoxicity of aminoglycosides.
    Martínez-Salgado C; López-Hernández FJ; López-Novoa JM
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):86-98. PubMed ID: 17602717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
    de Jager P; van Altena R
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides.
    Raveh D; Kopyt M; Hite Y; Rudensky B; Sonnenblick M; Yinnon AM
    QJM; 2002 May; 95(5):291-7. PubMed ID: 11978900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity of dactimicin, a novel pseudo-disaccharide aminoglycoside possessing the N-formimidoyl group, compared with that of astromicin, amikacin and other aminoglycoside antibiotics in animals.
    Inouye S; Niizato T; Shomura T; Kitasato I
    Drugs Exp Clin Res; 1989; 15(5):189-209. PubMed ID: 2791871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycoside nephrotoxicity: keys to prevention.
    Levin ML
    J Crit Illn; 1994 Oct; 9(10):911-2, 915. PubMed ID: 10150695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.